Loading
Life sciences · Journal article
Frontiers in Immunology · October 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cellular senescence is a stress-responsive state marked by sustained proliferative arrest and changes in metabolism, chromatin organization, secretion, and immune signaling. In ovarian cancer (OC), platinum therapy and PARP inhibition can generate senescence-associated states with distinct consequences. Their effects depend on treatment context, cellular compartment, stability of arrest, and the surrounding immune state. Therapy-induced senescent tumor cells may increase antigen presentation and inflammatory signaling and, in immune-competent settings, facilitate dendritic-cell and CD8+ T-cell responses. Persistent senescence can instead maintain a SASP that remodels stromal and immune compartments and may support residual disease, dissemination, or relapse. OC studies have linked altered senescence responses to cisplatin resistance, while senescence-associated states have also been reported after PARP inhibition and taxane treatment. Senescence in CAFs, mesothelial cells, adipose-associated stroma, and immune cells can further alter tumor-cell survival, invasion, immune surveillance, and treatment response. We therefore distinguish stable TIS from reversible senescence-like or dormant states and separate tumor-cell effects from stromal and immune effects. Senolysis, SASP modulation, ferroptosis, and immune-mediated clearance represent potential strategies, but most evidence remains preclinical. Overall, senescence in OC is best viewed as a context-dependent state that can either support antitumor immunity or facilitate immune escape and treatment persistence.